Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Growth Rate of the Dermatological Drugs Market?
In recent times, there has been substantial growth in the market size of dermatological drugs. This market is set to expand from $20.06 billion in 2024 to $22.04 billion in 2025, showcasing a compound annual growth rate (CAGR) of 9.8%. The expansion experienced in the historic period is traceable to the increased occurrence of skin disorders, progress in the formulation and delivery of drugs, heightened awareness of skincare and aesthetics, the growth of the elderly population, and increased interest in over-the-counter dermatological products.
What Growth Rate Is Forecasted for the Dermatological Drugs Market by 2029?
The market for dermatological drugs is predicted to experience considerable growth in the coming years, expanding to a sizable $31.75 billion by 2029 with a compound annual growth rate (CAGR) of 9.6%. This anticipated growth in the forecasted time frame can be credited to the advancement in biologics and targeted treatment approaches, escalating adoption of teledermatology and digital health services, the growth in the occurrence of skin conditions tied to lifestyle habits, increased demand for customised and regenerative medications, and extensive research in the realm of microbiome-related dermatological therapies. Key trends to watch out for during the forecast period encompass drug delivery based on nanotechnology, AI-powered dermatological diagnostic tools, therapies focused on microbiome, skin regeneration through 3D bioprinting, as well as treatments utilising gene editing and RNA.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21166&type=smp
Which Key Companies Are Shaping the Future of the Dermatological Drugs Market?
Major companies operating in the dermatological drugs market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Bayer AG, AstraZeneca plc, Novartis AG, GlaxoSmithKline Plc, Eli Lilly and Company, Amgen Inc., Bausch Health Companies Inc., Organon International, Galderma, Incyte Corporation, Glenmark Pharmaceuticals Ltd., Mayne Pharma Group Limited, Dermavant Sciences Inc., Taro Pharmaceutical Industries Ltd., Biofrontera AG, Almirall SA, UCB SA, LEO Pharma A/S, Dermira Inc.
Which Factors Are Driving Demand in the Dermatological Drugs Industry?
The increasing prominence of cosmetic dermatology procedures is poised to boost the dermatological drugs market’s expansion. Cosmetic dermatology, a specialized subsection of dermatology, aims to improve an individual’s physical appeal through numerous non-invasive treatments and regimens. There is a growing demand for these aesthetic treatments due to improved consumer consciousness, advancements in skincare methodologies, and a heightened inclination towards non-surgical procedures to enhance beauty and fight signs of aging. This amplified requisition for procedures like anti-aging and skin rejuvenation fuels the creation of cutting-edge dermatological medications that provide safe, efficient, and least invasive answers. For example, in January 2023, the International Society of Aesthetic Plastic Surgery, a professional institution based in the US, reported over 12.8 million surgical and 17.5 million non-surgical procedures performed globally, marking a 19.3% increase from the last recorded period. It is also projected that over 14.9 million surgical and 18.8 million non-surgical treatments will be executed worldwide by plastic surgeons in 2022, indicating an 11.2% surge in total procedures. Therefore, the escalation in cosmetic dermatology processes is propelling the dermatological drugs market’s growth.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21166&type=smp
How Is the Dermatological Drugs Market Segmented by Several Divisions?
The dermatological drugs market covered in this report is segmented –
1) By Drug Class: Corticosteroids, Retinoids, Antibiotics, Antifungals, Calcineurin Inhibitors, Other Drug Classes
2) By Administration: Topical Administration, Oral Administration, Parenteral Administration
3) By Indication: Acne, Psoriasis, Rosacea, Alopecia, Other Indications
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels
Subsegments:
1) By Corticosteroids: Topical Corticosteroids, Oral Corticosteroids, Injectable Corticosteroids
2) By Retinoids: Topical Retinoids, Oral Retinoids
3) By Antibiotics: Topical Antibiotics, Oral Antibiotics
4) By Antifungals: Topical Antifungals, Oral Antifungals
5) By Calcineurin Inhibitors: Topical Calcineurin Inhibitors, Systemic Calcineurin Inhibitors
6) By Other Drug Classes: Biologics, JAK Inhibitors, Antihistamines, Photodynamic Therapy Agents
What are the Emerging Market Trends Driving the Growth of the Dermatological Drugs Industry?
Focusing on the creation of biologic treatments for chronic skin conditions such as psoriasis, atopic dermatitis, and hidradenitis suppurativa is a key priority for leading players in the dermatological drugs market. These biologics are designed to interact with specific immune pathways, providing a more sustained and effective solution than conventional treatments. As an example, in September 2024, the American pharmaceutical firm, Eli Lilly and Company, secured approval for Ebglyss (lebrikizumab), a specialty interleukin-13 (IL-13) inhibitor. This drug is designed to treat moderate-to-severe atopic dermatitis in adults and children aged 12 and above. This approval signified a considerable progression in the field by presenting a new biologic treatment avenue for patients who fail to achieve sufficient symptom control with topical therapies. Ebglyss is intended to enhance patient quality of life by decreasing the severe itching and skin inflammation typically associated with moderate-to-severe atopic dermatitis.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/dermatological-drugs-global-market-report
Which Regions Are Driving Growth in the Dermatological Drugs Market?
North America was the largest region in the dermatological drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dermatological drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21166
This Report Delivers Insight On:
1. How big is the dermatological drugs market, and how is it changing globally?
2. Who are the major companies in the dermatological drugs market, and how are they performing?
3. What are the key opportunities and risks in the dermatological drugs market right now?
4. Which products or customer segments are growing the most in the dermatological drugs market?
5. What factors are helping or slowing down the growth of the dermatological drugs market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model